Alkermes PLC
Cerrado
SectorSanidad
50.18 4.32
Resumen
Variación precio
24h
Mínimo
47.88
Máximo
51.57
Ingresos | -116M -66M |
|---|---|
Ventas | 8.4M 393M |
P/B Media del Sector | 51.133 50.958 |
BPA | 0.38 |
Margen de beneficios | -16.92 |
Empleados | 2,050 |
EBITDA | -98M -22M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +4.01% upside |
Próximas Ganancias | 28 jul 2026 |
|---|
Capitalización Mercado | 2B 7.7B |
|---|---|
Apertura anterior | 45.86 |
Cierre anterior | 50.18 |
Noticias sobre sentimiento de mercado
By Acuity
10%
90%
13 / 342 Clasificación en Healthcare
Alkermes PLC Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
